In contrast, BRAF mutant colorectal cancers that count for approximately 10% of all cases, show only a marginal response rate of 5% (Prahallad et al. 2012), suggesting that colorectal cancers have an intrinsic resistance mechanism that appears to be absent or less common in melanoma. The gene discussed is BRAF; the disease is melanoma.